CHN2 and viral infectious disease: The TOA assay showed that Z-Tyr-Ala-CHN2 antiviral activity was lost when administered at 2 h post virus infection or later, suggesting that the compound targets one of the early steps in the SARS-CoV-2 replication cycle (Figure 5A).